Contineum Therapeutics, Inc. (CTNM) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-74.9%

$2.40

vs $9.56 price

Levered DCF

$2.43

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

16.76

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	-5.27×	-8.99×	118.46×	-15.88×	-13.39×
P/B	1.21×	1.91×	-5.7×	9.86×	6.28×
P/S	0×	0×	7.74×	0×	0×
EV / EBITDA	-3.68×	-8.64×	23.95×	-16.46×	-13.67×
Gross margin	0.0%	0.0%	100.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	-32.2%	0.0%	0.0%
Net margin	0.0%	0.0%	45.4%	0.0%	0.0%
Current ratio	27.5×	20.69×	23.29×	6.41×	18.99×
Debt / equity	0.03×	0.03×	-2.84×	0.15×	0.08×
Interest coverage	0×	0×	-77.29×	-58.56×	-86.29×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	-23.0%	-21.3%	-33.4%	-61.8%	-47.1%
Return on invested capital	-25.3%	-24.9%	-12.6%	-47.2%	-42.1%
Return on assets	-21.7%	-19.9%	17.4%	-47.9%	-41.1%
Free cash flow yield	-17.5%	-8.8%	4.9%	-5.2%	-6.8%
Earnings yield	-18.9%	-11.2%	5.9%	-6.3%	-7.5%
Enterprise value	$249.3M	$363.1M	$564.7M	$387.3M	$387.3M
Net debt / EBITDA	0.99×	0.37×	7.54×	-0.01×	-0.01×
Cash conversion cycle (days)	0	-2,562	0	0	0